Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 08 tags : Phase 3 save search
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
Published: 2021-06-08 (Crawled : 20:00) - biospace.com/
CTXR | $0.772 5.15% 4.9% 670K
|
Health Technology
|
| O: 3.92%
H: 1.51%
C: -3.02%
phase 3 trial milestone
Chinook Therapeutics Presents BION-1301 Interim Phase 1/2 Data in Patients with IgA Nephropathy (IgAN) at the 58th ERA-EDTA Virtual Congress
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: 2.33%
H: 10.28%
C: 2.78%
phase 1 nephropathy phase 3 phase 2 igan
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting
Published: 2021-06-08 (Crawled : 13:00) - beyondspringpharma.com
BYSI | $2.26 7.11% 6.64% 110K
|
Health Technology
|
| O: 1.07%
H: 0.64%
C: -5.31%
presentation therapy phase 3 plinabulin
Oramed Reaches 50% Enrollment in Phase 3 Oral Insulin Study
Published: 2021-06-08 (Crawled : 13:00) - biospace.com/
ORMP A | $2.39 2.58% 2.51% 31K
|
Health Technology
|
| O: 0.37%
H: 2.71%
C: 1.47%
insulin phase 3 enroll
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO | $10.34 3.19% 3.09% 240K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease
Published: 2021-06-08 (Crawled : 12:15) - biospace.com/
CLPT | $5.505 -0.09% -0.09% 55K
|
Health Technology
|
| O: 1.92%
H: 0.46%
C: -2.96%
disease phase 1 parkinson phase 3 phase 2
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
Published: 2021-06-08 (Crawled : 12:15) - globenewswire.com
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 2.29%
H: 0.12%
C: -1.12%
phase 3 trial
Progress Report for Phase 1 and Phase 2 of Nouveau Monde’s Bécancour Battery Anode Material Plants
Published: 2021-06-08 (Crawled : 08:00) - globenewswire.com
NMG | $1.95 -2.5% 0.0% 98K
|
Mining, Quarrying, and Oil and ...
|
| O: 1.11%
H: 1.01%
C: -1.6%
OLN | $53.56 -0.52% -0.5% 650K
|
Process Industries
|
| O: 0.0%
H: 2.94%
C: 1.95%
phase 2 battery phase 1 phase 3
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.